Expands pipeline of disease-modifying therapies for Alzheimer’s and Parkinson’s, adds gene therapies focused on AAV treatments, bolsters biosimilars portfolio.
Offers customizable solutions to help advance drug development, including pilot scale and process development support labs that offer non-GMP lab space.